Navigation Links
Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update
Date:8/4/2009

al Cancer (CRC): Presented new progression-free survival (PFS), disease control and neurotoxicity data from a randomized, controlled Phase 2 trial of picoplatin for the first-line treatment of metastatic CRC at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting. The results continue to support picoplatin as a neuropathy-sparing alternative to oxaliplatin with similar anti-tumor activity as assessed by PFS and disease control measured by tumor response rate. New data derived by three independent assessments indicated a statistically significant reduction in neurotoxicities with the use of picoplatin in the FOLPI regimen compared with oxaliplatin in the FOLFOX regimen (p<0.0019).

  • Castration-Resistant Prostate Cancer (CRPC): Presented new progression-free survival data from a Phase 2 clinical trial of picoplatin for the first-line treatment of patients with metastatic CRPC at the 2009 ASCO Annual Meeting. The updated efficacy and safety data demonstrated that picoplatin in combination with docetaxel and prednisone is active as first-line therapy for metastatic CRPC as demonstrated by several endpoints, including reductions in prostate specific antigen (PSA) levels, disease control as measured by tumor response, and PFS. Results also continue to show that picoplatin can be safely administered every three weeks for up to 10 cycles concurrently with full doses of docetaxel and prednisone, the standard treatment for CRPC. In addition, no neurotoxicity was observed in these patients.

Corporate Developments

  • Announced the appointment of Gary A. Lyons to the Board of Directors in July 2009. His appointment increases the number of directors to 10. Mr. Lyons has been and will continue to serve as a consultant to Poniard on matters of corporate and business development as the Company moves forward with its commercialization and par
    '/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Poniard Pharmaceuticals to Host Second Quarter 2009 Financial Results Conference Call on August 4
2. Poniard Pharmaceuticals Appoints Gary A. Lyons to Board of Directors
3. Poniard Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
4. Poniard Pharmaceuticals Files Shelf Registration
5. Poniard Pharmaceuticals to Present at the Leerink Swann Oncology Roundtable Conference
6. Poniard Pharmaceuticals to Present at the 2009 BIO International Convention
7. Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer
8. Poniard Pharmaceuticals to Present Final Data from Picoplatin Phase 1 Clinical Trials at American Association for Cancer Researchs 100th Annual Meeting
9. Poniard Pharmaceuticals Reschedules Fourth Quarter and Fiscal 2008 Results Conference Call for Monday, March 16
10. Poniard Pharmaceuticals to Host Fourth Quarter and Year-End 2008 Financial Results Conference Call on March 12
11. Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... CA (PRWEB) January 15, 2014 ... research solutions, today announced that Lupin Limited, one of ... Freeslate’s CM Protégé PharmD System for high ... Mumbai, India, is focused on a wide range of ...
(Date:1/14/2014)... CA (PRWEB) January 14, 2014 Histogen, ... the products of cells grown under simulated embryonic conditions, ... license agreement with Suneva Medical, Inc. for physician-dispensed aesthetic ... , This agreement is an amendment to ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014  Organovo announced ... from the National Institutes of Health (NIH) to help ... effective treatments to patients on a faster timeline. Organovo ... Sciences (NCATS) and the National Eye Institute (NEI) to ...
(Date:1/14/2014)... 2014   Kinaxis ®, provider of RapidResponse ®, a ... operations planning ( S&OP ) service, is proud to be ... will be held at the Hilton San Diego Bayfront, January ... Elisabeth Kaszas , Director of Supply Chain at Amgen, ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... 7 Cord Blood America, Inc. (OTC Bulletin Board: ... ( http://www.cordblood-america.com ) focused on ... families nationwide and internationally, said today it has begun ... secure cryogenic stem cell bank for the storage of ...
... VALLEY, Calif., May 6 Spectros Corporation (Portola ... against Thermo Fisher Scientific (NYSE: TMO ... by TMO,s Nanodrop 3300 product. Spectros invented and ... on white LEDs, and incorporated these into its ...
... OAKS, Calif., May 6 Amgen (Nasdaq: ... company,s Annual Meeting of Stockholders, held at The St. ... of outstanding shares were represented at the meeting.The director ... Carbonnel, Jerry D. Choate, Vance D. Coffman, Frederick W. ...
Cached Biology Technology:Cord Blood America to Acquire or Build Its Own Stem Cell Laboratory 2Spectros Corporation Protects Its Cool White LED Spectroscopy Technology Against Alleged Infringement by Thermo Fisher Scientific 2Amgen Announces Voting Results Of Annual Meeting Of Stockholders 2
(Date:7/10/2014)... natural-color satellite image was collected by the Moderate Resolution ... 10, 2014. Each hot spot, which appears as a ... on the MODIS instrument recognized temperatures higher than background. ... image, such hot spots are diagnostic for fire. ... little danger coming directly from the fires, although the ...
(Date:7/10/2014)... The yellow crazy ant Anoplolepis gracilipes is ranked ... responsible for catastrophic ecological impacts on islands. A new study ... examines and assesses the effects and dangers of the ... of the mature palm forest of the Valle de Mai, ... palm forest of Valle de Mai is a unique ecosystem ...
(Date:7/9/2014)... July 10, 2014 Inflammatory diseases can occur ... complicating treatment because a medication effective for one ... is the anti-arthritic medication dexamethasone, which alleviates joint ... study in the August issue of The ... of a new class of anti-arthritic drugs, specifically ...
Breaking Biology News(10 mins):Invasion of yellow crazy ant in a Seychelles UNESCO palm forest: Threats and solutions 2New class of anti-arthritis drugs effectively treats multiple inflammatory diseases 2
... La Jolla, CA - Salk Institute professor Terrence J. ... the neural networks revolution in computing in the 1980s, ... of Sciences. The Academy made the announcement today during ... the Academy recognizes distinguished and continuing achievements in original ...
... CARSON CITY, Nev. , April 27 State of ... by participating in The Prevention Plan™, a U.S. Preventive Medicine® program designed to ... before they progress. The program is projected to save Nevada ... , , ...
... , ATLANTA , April 27   Georgia Power received approval April 20 ... more solar options. , , , ... , , ... to include the following: , , , ...
Cached Biology News:Salk scientist Terrence Sejnowski elected to National Academy of Sciences 2U.S. Preventive Medicine Helps Participants of the State of Nevada Public Employees' Benefits Program (PEBP) Become Healthier 2U.S. Preventive Medicine Helps Participants of the State of Nevada Public Employees' Benefits Program (PEBP) Become Healthier 3Georgia Power's Green Energy Program Redesigned to Include More Solar Power 2
This buffer is Specifically formulated to be used with Endogen's Poly-HRP Streptavidin...
... Analyst Software has been optimized for the ... allow the software to quickly and accurately ... well of an ELISA plate or each ... Software has been customized to incorporate standard ...
... An easy-to-use solution that enables fully automated ... 400 Hybridization Station has been designed to ... the throughput necessary to perform a wide ... performed in the range 485C; denaturations of ...
The Piezo Power MicroDissection (PPMD) system is designed for rapid isolation of single cells or small cell areas...
Biology Products: